Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography

This publication has 23 references indexed in Scilit:

• High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib
  The Hematology Journal, 2004
• Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
  Blood, 2003
• Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib
  Blood, 2003
• Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
  New England Journal of Medicine, 2003
• PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
  Science, 2003
• Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment
  Blood, 2002
• A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
  Blood, 2002
• Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
  New England Journal of Medicine, 2002
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
  Science, 2001
• Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR
  Leukemia, 1999